News | May 07, 2026
Neuland Labs and LIR Life partner on next-gen transdermal GLP-1 obesity therapy platform
LIR Life is working on a patch-based, transdermal delivery system for GLP-1 therapies targeting obesity
LIR Life is working on a patch-based, transdermal delivery system for GLP-1 therapies targeting obesity
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
SBE303 targets Nectin-4, an adhesion protein overexpressed in multiple tumor types, including urothelial, lung, and breast cancers
The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
